MedTrace Logo

Study on the Management of COMISA

NCT07743931 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-08-04

No results posted yet for this study

Summary

COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.

Conditions

  • Obstructive Sleep Apnea (OSA)
  • Insomnia
  • COMISA

Interventions

DRUG

Daridorexant 50 mg

Daridorexant initiated for 1 month before CPAP and prescribed as part of routine care.

DEVICE

Continuous Positive Air Pressure (CPAP)

PAP therapy initiated after 1 month of Daridorexant, according to standard clinical practice.

Sponsors & Collaborators

  • Polyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve

    collaborator UNKNOWN

  • Hôpital Européen Marseille

    collaborator OTHER

  • Centre Médical les Jasmins "Poumon et Sommeil"

    collaborator UNKNOWN

  • Hôpital de la Pitié Salpêtrière - AP-HP

    collaborator UNKNOWN

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Jean-Louis PEPIN, Pr · GRENOBLE ALPES UNIVERSITY HOSPITAL

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-06-30
Completion
2029-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743931 on ClinicalTrials.gov